Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio

ProductsSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Spectrum has four FDA-approved oncology/hematology products and three products in late-stage development. The company also has as a diversified portfolio of proprietary drugs in various stages of development, with a focus on oncology/hematology.

Click any area on the chart below to learn more on a specific drug.

Spectrum Pharmaceuticals, Inc. product portfolio

Back to top

Fusilev
MarqiboMarqibo Zevalin SPI-1620 SPI-1620 Renazorb SPI-2012 Belinostat Ozarelix Captisol-enabled Melphalan Belinostat EOquin Apaziquone Pralatraxate